Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Event, Product/Service, Trade Show, Webcast

Wugen Announces Data Presentation at the 63rd Annual Society of Hematology (ASH) Annual Meeting


Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced it will present preclinical data on the characterization of WU-CART-007 at the 63rd Annual Meeting of the American Society of Hematology (ASH) which will be held virtually and in-person in Atlanta, Georgia from December 11-14, 2021. The results demonstrate preclinical safety and anti-tumor activity of WU-CART-007. Wugen is preparing to begin enrollment for a Phase 1/2 clinical trial for relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (LBL) (NCT#04984356).

The details of Wugen's presentation at ASH are as follows:

About Wugen

Wugen, Inc., is a clinical-stage biotechnology company developing a pipeline of off-the-shelf memory NK and CAR-T cell therapies to treat a broad range of hematological and solid tumor malignancies. Memory NK cells are hyper-functional, long-lasting immune cells that have evolved to attack cancer and respond to infection. Wugen is harnessing the power of this rare cell population by using its proprietary technologies to create WU-NK-101, currently in clinical development for acute myelogenous leukemia (AML). Wugen is also advancing WU-CART-007, currently in development for T-cell acute lymphoblastic leukemia (T-ALL). For more information, please visit www.wugen.com.


These press releases may also interest you

at 18:59
Today, the U.S. Food and Drug Administration took two actions to expand the use of the antiviral drug Veklury (remdesivir) to certain non-hospitalized adults and pediatric patients for the treatment of mild-to-moderate COVID-19 disease. This provides...

at 18:25
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted expedited approval of a supplemental new drug application (sNDA) for Veklury® (remdesivir) for the treatment of non-hospitalized adult and adolescent...

at 18:00
Constellation Software Inc. announced today it intends to release its fourth quarter results on February 10, 2022. The Company's quarterly results will be disseminated via press release and made available on the Company's website...

at 18:00
Topicus.com Inc. announced today it intends to release its fourth quarter results on February 8, 2022. The Company's quarterly results will be disseminated via press release and made available on the Company's website (www.topicus.com) and SEDAR,...

at 18:00
Hörmann Northwest Door is providing notice of a recent event that may affect the security of certain information. On September 1, 2021, Hörmann Northwest Door received a report of issues related to the functionality of its email system.  Hörmann...

at 16:53
Full View Marketing LLC today formally announced the relaunch of their flagship software app, Inspector Toolbelt. It brings cutting-edge technology to the home inspection industry, and according to the founders, this is just the beginning. The...



News published on 4 november 2021 at 16:20 and distributed by: